PCN189 CANCER RISK AMONG PATIENTS WITH SCHIZOPHRENIA

Abstract

Determine Cancer rates among patients with Schizophrenia Claims data from The Healthcare Utilization Project (HCUP) and TriNetX was used to identify patient outcomes. ICD-10 codes were used to determine Cancer rates among patients with Schizophrenia and the control group. The HCUP data was limited to the year 2016 while the TriNetX data is from 2003-2019. Inclusion criteria for both data sets were limited to Schizophrenia (ICD-10: F20). Exclusion criteria for HCUP was based on Schizophrenia diagnosis, in TriNetX we excluded anyone with a mood disorder (MDD and BPD). Smoking rates were imputed using [(a * RR +b)/(c * RR +d) * the expected number of cancers in the control group] based on reported smoking rates of patients with Schizophrenia. The Schizophrenia patients were matched to controls based on age and sex using five years increments. In the HCUP dataset 240,000 patients were matched based on age and sex. All cancer subtypes among the schizophrenia group were reduced compared to the control. Lung, Bladder, Ovarian and Kidney cancer had the lowest risk ratios with imputed smoking rates (0.15, 0.11, 0.27, and 0.29 respectively). The TriNetX dataset has yet to be analyzed however we expect to find a similar reduction in overall cancer rates in this population. This study confirms previous findings in the literature suggesting schizophrenia patients have lower cancer rates than the general population. These findings however, contradict the expected cancer findings given these patients smoke at a prevalence of ∼65% and other lifestyle factors predispose them to increased cancer rates. This suggests that these findings can be explained by screening rates, genetics, administrative claims bias or an off target drug effect. More research is needed to determine what is driving this reduction in overall cancer rates in this patient population.